StockData
BioVie Inc. logo

BioVie Inc. (BIVI) stock

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$0.94−0.05 (-5.27%)

Close on Nov 18, 2026Market cap $7.11MP/E –Yield –

BioVie operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BioVie's operating cash flow for the twelve months ending Jun 30, 2026 was -$19.02M. For fiscal 2026 it was -$19.02M. The highest annual figure on record is -$2.51K in fiscal 2013.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$19.02M–
FY2025Jun 30, 2025-$19.03M–
FY2024Jun 30, 2024-$27.95M–
FY2023Jun 30, 2023-$40.25M–
FY2022Jun 30, 2022-$18.99M–
FY2021Jun 30, 2021-$10.45M–
FY2020Jun 30, 2020-$1.63M–
FY2019Jun 30, 2019-$2.50M–
FY2018Jun 30, 2018-$621.34K–
FY2017Jun 30, 2017-$623.62K–
FY2016Jun 30, 2016-$153.63K–
FY2015Jun 30, 2015-$65.38K–
FY2014Jun 30, 2014-$172.83K–
FY2013Jun 30, 2013-$2.51K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$4.12M–
Q3 FY2026CQ1 2026Mar 31, 2026-$7.44M–
Q2 FY2026CQ4 2025Dec 31, 2025-$4.44M–
Q1 FY2026CQ3 2025Sep 30, 2025-$3.02M–
Q4 FY2025CQ2 2025Jun 30, 2025-$5.61M–
Q3 FY2025CQ1 2025Mar 31, 2025-$1.25M–
Q2 FY2025CQ4 2024Dec 31, 2024-$8.58M–
Q1 FY2025CQ3 2024Sep 30, 2024-$3.58M–
Q4 FY2024CQ2 2024Jun 30, 2024-$4.01M–
Q3 FY2024CQ1 2024Mar 31, 2024-$5.85M–
Q2 FY2024CQ4 2023Dec 31, 2023-$5.91M–
Q1 FY2024CQ3 2023Sep 30, 2023-$12.18M–
Q4 FY2023CQ2 2023Jun 30, 2023-$11.29M–
Q3 FY2023CQ1 2023Mar 31, 2023-$11.74M–
Q2 FY2023CQ4 2022Dec 31, 2022-$8.01M–
Q1 FY2023CQ3 2022Sep 30, 2022-$9.22M–
Q4 FY2022CQ2 2022Jun 30, 2022-$5.87M–
Q3 FY2022CQ1 2022Mar 31, 2022-$5.88M–
Q2 FY2022CQ4 2021Dec 31, 2021-$4.71M–
Q1 FY2022CQ3 2021Sep 30, 2021-$2.53M–
Q4 FY2021CQ2 2021Jun 30, 2021-$7.01M–
Q3 FY2021CQ1 2021Mar 31, 2021-$1.04M–
Q2 FY2021CQ4 2020Dec 31, 2020-$1.32M–
Q1 FY2021CQ3 2020Sep 30, 2020-$1.08M–
Q4 FY2020CQ2 2020Jun 30, 2020-$360.02K–
Q3 FY2020CQ1 2020Mar 31, 2020-$401.39K–
Q2 FY2020CQ4 2019Dec 31, 2019-$275.90K–
Q1 FY2020CQ3 2019Sep 30, 2019-$590.91K–
Q4 FY2019CQ2 2019Jun 30, 2019-$631.69K–
Q1 FY2019CQ3 2018Dec 31, 2018-$1.21M–
Q4 FY2018CQ2 2018Jun 30, 2018-$209.28K–
Q3 FY2018CQ1 2018Mar 31, 2018-$48.75K–
Q2 FY2018CQ4 2017Dec 31, 2017-$159.88K–
Q1 FY2018CQ3 2017Sep 30, 2017-$203.44K–
Q4 FY2017CQ2 2017Jun 30, 2017-$125.17K–
Q3 FY2017CQ1 2017Mar 31, 2017-$268.72K–
Q2 FY2017CQ4 2016Dec 31, 2016-$101.71K–
Q1 FY2017CQ3 2016Sep 30, 2016-$128.01K–
Q4 FY2016CQ2 2016Jun 30, 2016-$119.39K–

More BioVie figures

See a number that looks wrong?